lonafarnib (Sarasar)

From Aaushi
Jump to navigation Jump to search

Indications

Mechanism of action

More general terms

Additional terms

References

  1. Gordon LB, Shappell H, Massaro J et al Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1687-1695 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710166 https://jamanetwork.com/journals/jama/fullarticle/2679278?
    Hisama FM, Oshima J. Precision Medicine and Progress in the Treatment of Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1663-1664. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710145 https://jamanetwork.com/journals/jama/fullarticle/2679255
  2. Gordon LB, Kleinman ME, Massaro J et al Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27400896 Free PMC Article

Database